AHEAD A3-45

The BBRC is one of the centers selected to participate in the AHEAD trial. The study plans to bring together 1,400 participants from around the world to evaluate the efficacy and safety of a monoclonal antibody directed against the beta-amyloid protein, lecanemab, to prevent Alzheimer's disease in people between 55 and 80 years of age who are at high risk of developing it. The selected participants will undergo the tests described in the trial protocol at the BBRC facilities, such as neuropsychological tests and MRI scans, among others. The study drug will also be administered to those who meet all the criteria.